Video
Novel MV140 vaccine is “game changing” for recurrent UTIs
Author(s):
Video Player is loading.
In this video, J. Curtis Nickel, MD, discusses the unmet need for a preventive treatment for patients with recurrent urinary tract infections (UTIs). At the 2021 AUA Annual Meeting, Nickel shared results from the groundbreaking study, "“A novel sublingual vaccine will dramatically alter the clinical management of recurrent urinary tract infections in women.”
Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.
Related Videos
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
